{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ALMS",
  "name": "Alumis Inc.",
  "url": "https://frontierpicks.com/dossiers/ALMS/",
  "json_url": "https://frontierpicks.com/dossiers/ALMS.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Psoriasis leg is fully told — 2026-08-10 ONWARD3 48-week data (75% PASI 90 / 54% PASI 100) left the stock 16.5% under its $30.30 52-week high. The only re-rating leg left is the undated LUMUS Phase 2b lupus topline, reaffirmed for Q3 2026 on the 2026-08-13 Q2 release. Binary headline risk is any-session through 2026-09-30.",
  "invalidation_trigger": "A weekly close below $22 round-trips the April–June rising base that carried the stock from ~$20 into the high $20s; secondarily, a LUMUS Phase 2b SLE primary-endpoint miss, or 2026-09-30 passing with no topline and re-guided timing.",
  "catalyst_date": "2026-09-15",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "LUMUS Phase 2b SLE topline is guided to Q3 2026 and is NOT date-certain; enrollment is complete, so any session through 2026-09-30 carries binary headline risk.",
    "Pre-revenue: the only reported top line is collaboration revenue ($1.7M in Q2 2026). No product revenue is possible before an approval.",
    "Theme tag 'Oncology & immunology' is a registry misnomer — Alumis is pure immunology (oral TYK2 for psoriasis and lupus) with no oncology program.",
    "Competitor read-across is direct: Takeda's zasocitinib and BMS's Sotyktu datasets can reprice ALMS with no news from Alumis itself.",
    "Any published beta for ALMS is distorted by the 2026-01-06 +95.31% single-session gap; the name is not a macro hedge.",
    "Equity funding into strength is the established pattern: a $17.00 follow-on of 20.3M shares closed 2026-01-09, days after the January re-rate."
  ],
  "body_markdown": "\n\"# ALMS — Alumis Inc.\n\n## Current Thesis\nThe psoriasis leg of this story is finished being told. On 2026-08-10 Alumis released ONWARD3 long-term-extension topline showing 75% of patients at PASI 90 and 54% at PASI 100 after up to 48 weeks of continuous envudeucitinib (n=773) — the strongest durability dataset the company has produced — and the stock closed 2026-08-14 at $25.31, 16.5% below its 52-week high of $30.30. Good clinical news is now being absorbed rather than extended. What remains buyable is one undated event: the potentially pivotal LUMUS Phase 2b topline in systemic lupus erythematosus, reaffirmed for Q3 2026 on the 2026-08-13 Q2 release. A clean primary-endpoint hit opens the type-I interferon axis (Sjögren's and cutaneous lupus are already named as follow-ons) and re-rates envudeucitinib beyond dermatology; a miss leaves a well-characterised oral psoriasis pill entering a field where Sotyktu is entrenched and Takeda's zasocitinib is advancing. Enrollment is complete and the guided window closes 2026-09-30, so headline risk is any-session.\n\n**The narrative is maturing.** The dating: the 2026-01-06 Phase 3 psoriasis topline produced a +95.31% single session and drove the twelve-month re-rate; full Phase 3 data on 2026-03-28 extended it; but the 2026-08-10 48-week extension data did not carry price back toward $30.30, and HC Wainwright moved from Buy to Neutral on valuation with a $25 target reiterated on both 2026-08-03 and 2026-08-14. Dense coverage, incrementally positive data, no new high — the flow is moderating while the story still works.\n\n## Bull Case\n- **Durability now demonstrated (2026-08-10):** ONWARD3 LTE topline — 75% PASI 90 and 54% PASI 100 after up to 48 weeks, n=773. This addresses the standard objection to Week-16/Week-24 clearance data and feeds the NDA package.\n- **Phase 3 efficacy (full data 2026-03-28):** PASI 90 68.0%/62.1% and PASI 100 41.0%/39.5% at Week 24 across ONWARD1/ONWARD2.\n- **Regulatory step on the calendar:** NDA submission to FDA for moderate-to-severe plaque psoriasis remains on track for Q4 2026, reaffirmed 2026-08-13.\n- **Funded through both events:** $502.3M cash, cash equivalents and marketable securities at 2026-06-30, with stated runway into Q4 2027 — no forced raise before the lupus print.\n- **Cost line moving the right way:** Q2 2026 R&D $85.3M versus $108.8M in Q2 2025; G&A $23.4M versus $34.5M.\n- **Indication optionality is pre-specified:** Sjögren's disease and cutaneous lupus erythematosus named as the next interferon-driven targets, contingent on LUMUS; a Phase 2 biomarker trial of A-005 (CNS-penetrant TYK2) in Parkinson's is planned for H1 2027.\n- **Street still above the tape:** 11 analysts polled by S&P Global carry a Strong Buy consensus and an average target of $39.9.\n\n## Bear Case\n- **Q2 2026 missed on both lines (2026-08-13):** EPS $(1.11) against $(0.71) consensus; revenue $1.662M against $3.468M consensus. Net loss for the quarter was $142.2M.\n- **The sell-side is no longer uniformly bullish:** HC Wainwright downgraded to Neutral citing valuation and has reiterated Neutral/$25 twice this month (2026-08-03, 2026-08-14) — a published target sitting essentially on top of the 2026-08-14 close of $25.31, against a $39.9 consensus average. That dispersion is the disagreement about what lupus is worth.\n- **Best data of the year did not make a new high:** the 2026-08-10 release left price 16.5% under $30.30 four sessions later.\n- **LUMUS is Phase 2b in SLE**, historically the hardest immunology indication to read out cleanly; the trial is potentially pivotal, not confirmatory.\n- **Pre-revenue with a large burn:** the only reported top line is $1.7M of collaboration revenue in Q2 2026, against a $142.2M quarterly net loss.\n- **Crowded oral TYK2 field:** BMS's Sotyktu is the commercial incumbent; Takeda's zasocitinib is a competing next-generation molecule. Cross-trial clearance advantage does not settle formulary access or price.\n- **Equity funding into strength is the pattern:** a $17.00 follow-on of 20.3M shares closed 2026-01-09, days after the January re-rate.\n\n## Setup & Price Structure\n- Reference close 2026-08-14: **$25.31**. 52-week high **$30.30** (-16.5%). Three-month return +10.7%. RSI(14) 42.9 — mid-range, no overbought extension into the readout window.\n- The April–June advance built a rising base from roughly $20 into the high $20s. **$22** is the floor of that structure; the stock trading below the late-July high-$20s area means the market has already given back part of the summer premium ahead of the binary.\n- Positioning observables, stated as observables: news flow clustered — five headlines between 2026-08-03 and 2026-08-14, including a beat-quality clinical release and an earnings miss — with no new high out of it. The Q2 print is behind (2026-08-13), so there is **no scheduled earnings date inside the next 30 days**; the entire positioning question sits on an undated 8-K. The most recently published target ($25, 2026-08-14) is at the market; the consensus average ($39.9) is far above it.\n- No new equity filings appear in the recent record, but the January precedent means a post-readout financing is a live possibility either way the data breaks.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-15 (est.)** — LUMUS Phase 2b SLE topline. Company guidance is \"third quarter of 2026\" (reaffirmed 2026-08-13); this date is a mid-window placeholder, not a confirmed release date. Any session from now is live.\n- **2026-09-30** — hard outer edge of the guided Q3 window. If the quarter ends without topline, the guidance itself is the datapoint.\n- **Ongoing** — competitor read-across. Any zasocitinib or Sotyktu dataset or label action can reprice ALMS with nothing coming from Alumis.\n- Outside the window but relevant: **Q4 2026** NDA submission for plaque psoriasis; **H1 2027** Phase 2 biomarker trial start for A-005 in Parkinson's.\n\n## What Would Change Our Mind\nThe structure that has to hold is the April–June base. Its floor is $22: **a weekly close below $22** would mean the entire summer advance has been round-tripped and the market is discounting the lupus print negatively before it lands, which is a different situation from waiting on a coin-flip. Second, if 2026-09-30 passes with no LUMUS topline and the company re-guides, the undated-binary frame becomes a timing-slip frame and the name reverts to a psoriasis-launch story that has to be valued on commercial assumptions rather than optionality. Third, on the data itself: a primary-endpoint miss in LUMUS caps envudeucitinib in dermatology and removes the reason the stock carries a $39.9 consensus average. Conversely, a clear hit with a clean safety profile — and target revisions from the analysts currently sitting at $25 — would flip the read-through from binary-event to franchise. Fresh entries at $25.31 into an undated Phase 2b in SLE are a coin-flip on timing as well as outcome; the case for waiting for either the print or a lower base is stronger than the case for anticipating.\n\n## Correlation Notes\n- **TYK2 complex:** ALMS trades with read-across to BMS (Sotyktu, the commercial benchmark it is measured against) and Takeda (zasocitinib). A competitor efficacy or safety print moves ALMS without any Alumis news.\n- **Clinical-stage biotech beta:** long-duration, pre-revenue names track XBI-style risk appetite and rate expectations; a $142.2M quarterly loss against $502.3M of cash makes financing-window sentiment a direct input.\n- **Idiosyncratic dominance:** the 2026-01-06 +95.31% single session shows event risk swamps factor exposure here. Any published beta for this name is distorted by that gap and should not be read as a macro relationship.\"",
  "first_seen": "2026-07-07",
  "last_analyzed": "2026-08-16T13:46:54+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}